Monopar Therapeutics Files 8-K
Ticker: MNPR · Form: 8-K · Filed: Sep 15, 2025 · CIK: 1645469
| Field | Detail |
|---|---|
| Company | Monopar Therapeutics (MNPR) |
| Form Type | 8-K |
| Filed Date | Sep 15, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, 8-k
TL;DR
Monopar Therapeutics filed a routine 8-K on 9/15/25, no major news.
AI Summary
Monopar Therapeutics Inc. filed an 8-K on September 15, 2025, reporting on its corporate activities. The filing indicates no specific material events or financial updates were disclosed in this particular report, suggesting it may be a routine filing or related to administrative matters.
Why It Matters
This filing serves as a public record of corporate events for Monopar Therapeutics, which is important for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — The filing is a standard 8-K with no disclosed material events, indicating no immediate new risks.
Key Players & Entities
- Monopar Therapeutics Inc. (company) — Registrant
- September 15, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 1000 Skokie Blvd. , Suite 350 , Wilmette , IL 60091 (address) — Principal Executive Offices
- 847-388-0349 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing by Monopar Therapeutics?
This 8-K filing by Monopar Therapeutics on September 15, 2025, is a current report filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
What is Monopar Therapeutics' state of incorporation?
Monopar Therapeutics Inc. is incorporated in Delaware.
What is the address of Monopar Therapeutics' principal executive offices?
The principal executive offices of Monopar Therapeutics are located at 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091.
What is the telephone number for Monopar Therapeutics?
Monopar Therapeutics' telephone number, including area code, is (847) 388-0349.
Does this filing disclose any specific material events or financial statements?
Based on the provided text, this filing is a Form 8-K, but it does not detail specific material events or financial statements. It lists 'Regulation FD Disclosure' and 'Financial Statements and Exhibits' as items of information, but the content of these is not provided.
Filing Stats: 492 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2025-09-15 07:00:11
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value MNPR The Nasdaq Stock Mar
Filing Documents
- mnpr20250912_8k.htm (8-K) — 26KB
- ex_861328.htm (EX-99.1) — 13KB
- ex_861335.htm (EX-99.2) — 1KB
- ex_861336.htm (EX-99.3) — 9KB
- ex_861328img001.jpg (GRAPHIC) — 3KB
- poster.jpg (GRAPHIC) — 142KB
- slide01.jpg (GRAPHIC) — 93KB
- slide02.jpg (GRAPHIC) — 39KB
- slide03.jpg (GRAPHIC) — 77KB
- slide04.jpg (GRAPHIC) — 62KB
- slide05.jpg (GRAPHIC) — 65KB
- slide06.jpg (GRAPHIC) — 69KB
- slide07.jpg (GRAPHIC) — 77KB
- slide08.jpg (GRAPHIC) — 83KB
- slide09.jpg (GRAPHIC) — 93KB
- slide10.jpg (GRAPHIC) — 69KB
- slide11.jpg (GRAPHIC) — 86KB
- slide12.jpg (GRAPHIC) — 60KB
- slide13.jpg (GRAPHIC) — 58KB
- slide14.jpg (GRAPHIC) — 58KB
- 0001437749-25-029005.txt ( ) — 1744KB
- mnpr-20250915.xsd (EX-101.SCH) — 3KB
- mnpr-20250915_def.xml (EX-101.DEF) — 12KB
- mnpr-20250915_lab.xml (EX-101.LAB) — 15KB
- mnpr-20250915_pre.xml (EX-101.PRE) — 12KB
- mnpr20250912_8k_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On September 14, 2025, Monopar Therapeutics Inc. ("Monopar " ) issued a press release announcing the presentation of new data on the long-term neurological efficacy and safety of its investigational therapy ALXN1840 (tiomolybdate choline) for Wilson disease at the 150th American Neurological Association (ANA) Annual Meeting on September 14-15, 2025. The press release, poster presentation and oral presentation are furnished as Exhibit 99.1, 99.2 and 99.3, respectively, and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release Dated September 14, 2025 99.2 Poster Presentation on the Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease 99.3 Oral Presentation on the Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Monopar Therapeutics Inc. Date: September 15, 2025 By: /s/ Quan Vu Name: Quan Vu Title: Chief Financial Officer